Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Memory Revises Amgen Deal, Increases Focus On Clinical Candidates

This article was originally published in The Pink Sheet Daily

Executive Summary

New Jersey biotech will de-emphasize new drug discovery and reduce R&D workforce.

You may also be interested in...



Roche Cash Infusion Saves Partnered Memory Program, Allows Expanded Phase II Study

Memory halves its workforce to find funds for the cognitive impairment associated with schizophrenia program.

Roche Cash Infusion Saves Partnered Memory Program, Allows Expanded Phase II Study

Memory halves its workforce to find funds for the cognitive impairment associated with schizophrenia program.

Roche Licenses Memory’s Lead CNS Compound

Swiss firm exercises option on nicotinic alpha-7 receptor agonist, gives Memory needed cash infusion.

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel